Harvard Bioscience, Inc. entered into a third amendment to the Credit Agreement, dated as of December 22, 2020, among the Company, the lenders party thereto, and Citizens Bank, N.A., as the administrative agent, as further amended, restated, supplemented or otherwise modified from time to time.   The Credit Agreement provides that Consolidated EBITDA (as defined therein) may be increased by, among other things, the amount of certain non-recurring costs and expenses, provided that the amount of such increase shall not in any period exceed 10% of Consolidated EBITDA.   Pursuant to the Third Amendment, the Lenders and the Administrative Agent agreed to modify the definition of ?Consolidated EBITDA?

to provide that, notwithstanding the 10% Cap, Consolidated EBITDA may be increased by the amount of (i) the commission fee expected to be paid by the Company in relation to the Employee Retention Credit received in the fiscal year ending on or before December 31, 2024; and (ii) reserves and expenses related to finalizing an escheatment audit with the State of Delaware in a total amount equal to or around $600,000 expected to be paid during the second quarter of 2024.   The Third Amendment further provides that there are no fees, expenses or disbursements required to be paid in connection with the Third Amendment (other than reimbursable attorney costs as provided in Section 10.3 of the Credit Agreement).